June 2019 Trials of the Month

Type

Acronym

Study Title

Description

Site(s)

Breast

VIOLETTE

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes

  • Metastatic Triple Breast Cancer
  • Systemic Therapy

Odette Cancer Centre

GI

KEYNOTE-859

A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab Plus Chemotherapy vs. Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • Gastric or GE Junction Adenocarcinoma
  • Systemic Therapy

Odette Cancer Centre

GU

 AL-ACC-01 / ACCURACY

 

A Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

  • Recurrent or Metastatic Adenoid Cystic Carcinoma
  • Systemic Therapy

 

London Health Sciences Centre

HEME

PEV 3001

A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

  • 1st Line
  • Systemic Therapy

Odette Cancer Centre

MEL

LEAP 4

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants

· Stage III or IV

· Systemic Therapy

Odette Cancer Centre

Sarcoma

RESAR

REtroperitoneal SArcoma Registry (RESAR): Prospective Collection of Primary Retroperitoneal Sarcoma Patient’s Data, Radiological and Pathological Material for the TransAtlantic Retroperitoneal Sarcoma Working Group

· Retroperitoneal Sarcoma

· Observational Registry

The Ottawa Hospital

 

ANY

NIMBLe

A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay

  • Metastatic or Unresectable Solid Tumors
  • Systemic Therapy

Juravinski Cancer Centre